| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1053/J.ACKD.2013.09.004 |
| P8608 | Fatcat ID | release_sdkji2eqqzglzmhbp2licgay6u |
| P932 | PMC publication ID | 3950821 |
| P698 | PubMed publication ID | 24602463 |
| P2093 | author name string | Rujun Gong | |
| P2860 | cites work | In vitro induction of CD25+ CD4+ regulatory T cells by the neuropeptide alpha-melanocyte stimulating hormone (alpha-MSH) | Q74319170 |
| Glucocorticoid effects on bone | Q74645772 | ||
| Discovery and development of novel melanogenic drugs. Melanotan-I and -II | Q77370427 | ||
| IkappaB-NF-kappaB structures: at the interface of inflammation control | Q77726306 | ||
| Long-term Outcome of Adult Onset Idiopathic Minimal Change Disease | Q80524322 | ||
| alpha-MSH prevents impairment in renal function and dysregulation of AQPs and Na-K-ATPase in rats with bilateral ureteral obstruction | Q81272591 | ||
| Prevalence and characteristics of familial hyperaldosteronism: the PATOGEN study (Primary Aldosteronism in TOrino-GENetic forms) | Q84851934 | ||
| Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans | Q24323379 | ||
| ACTH protects against glucocorticoid-induced osteonecrosis of bone | Q24631407 | ||
| Treatment of nephrotic syndrome with adrenocorticotropic hormone (ACTH) gel | Q24632899 | ||
| H.p. Acthar gel and cosyntropin review: clinical and financial implications | Q24645310 | ||
| The melanocortin system | Q28205910 | ||
| Melanocortins and their Receptors and Antagonists | Q28208352 | ||
| Distribution of cDNA for melanocortin receptor subtypes in human tissues | Q28297582 | ||
| Amplitude, but not frequency, modulation of adrenocorticotropin secretory bursts gives rise to the nyctohemeral rhythm of the corticotropic axis in man. | Q30453648 | ||
| Structure-function of the G protein-coupled receptor superfamily | Q30576993 | ||
| The role of corticosteriods in the regulation of vascular tone | Q33634237 | ||
| Pharmacokinetic study of oral prednisolone compared with intravenous methylprednisolone in patients with juvenile dermatomyositis | Q33779452 | ||
| Glucocorticoid-remediable aldosteronism. | Q33795609 | ||
| The role of the transcription factor CREB in immune function | Q33920635 | ||
| The proopiomelanocortin system | Q33921597 | ||
| The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. | Q33943247 | ||
| Melanocortin 1 receptor agonists reduce proteinuria | Q34117792 | ||
| Melanocortin receptors: their functions and regulation by physiological agonists and antagonists | Q34226802 | ||
| Chronic treatment with a melanocortin-4 receptor agonist causes weight loss, reduces insulin resistance, and improves cardiovascular function in diet-induced obese rhesus macaques | Q34304856 | ||
| A review and update on melanocyte stimulating hormone therapy: afamelanotide | Q34359726 | ||
| Bremelanotide: an overview of preclinical CNS effects on female sexual function | Q34584136 | ||
| Evaluation of the safety and efficacy of bremelanotide, a melanocortin receptor agonist, in female subjects with arousal disorder: a double-blind placebo-controlled, fixed dose, randomized study. | Q34586801 | ||
| Thematic review series: skin lipids. Sebaceous gland lipids: friend or foe? | Q34708310 | ||
| Management of nephrosis; the use of long continued hormone therapy | Q34930608 | ||
| Signaling from the human melanocortin 1 receptor to ERK1 and ERK2 mitogen-activated protein kinases involves transactivation of cKIT. | Q34943036 | ||
| Podocyte biology and response to injury | Q35005456 | ||
| The melanocortin agonist AP214 exerts anti-inflammatory and proresolving properties | Q35069961 | ||
| Chronic glucocorticoid therapy amplifies glomerular injury in rats with renal ablation | Q35579156 | ||
| Targeting melanocortin receptors as a novel strategy to control inflammation. | Q35682900 | ||
| Crucial role of the melanocortin receptor MC1R in experimental colitis | Q35760868 | ||
| Glucocorticoid-mediated mineralocorticoid receptor activation and hypertension | Q35806295 | ||
| The melanocortin-4 receptor: physiology, pharmacology, and pathophysiology. | Q36003378 | ||
| Glomerular disease workshop. | Q36305204 | ||
| MAPK signal specificity: the right place at the right time | Q36444123 | ||
| The renaissance of corticotropin therapy in proteinuric nephropathies | Q36520242 | ||
| Studies on the physiological functions of the melanocortin system | Q36640631 | ||
| Cardiovascular and renal actions of melanocyte-stimulating hormone peptides | Q36672425 | ||
| AP214, an analogue of alpha-melanocyte-stimulating hormone, ameliorates sepsis-induced acute kidney injury and mortality | Q36681505 | ||
| Regulation of immune tolerance by anti-inflammatory neuropeptides | Q36691091 | ||
| Adrenocorticotropic hormone ameliorates acute kidney injury by steroidogenic-dependent and -independent mechanisms | Q36728787 | ||
| Inhibition of Rho is required for cAMP-induced melanoma cell differentiation. | Q36873446 | ||
| Anti-inflammatory neuropeptides: a new class of endogenous immunoregulatory agents | Q37206399 | ||
| Inducible rodent models of acquired podocyte diseases. | Q37265903 | ||
| Regulation of the hypothalamic-pituitary-adrenal axis | Q37538330 | ||
| Melanocortin 1 receptor and risk of cutaneous melanoma: a meta-analysis and estimates of population burden | Q37815455 | ||
| ACTH: a short introductory review | Q37824466 | ||
| Treatment of nephrotic syndrome with adrenocorticotropic hormone (ACTH). | Q37923991 | ||
| Childhood nephrotic syndrome--current and future therapies | Q38017937 | ||
| Immunotherapy in renal diseases | Q38019101 | ||
| Evidence that the insulin secretagogue, β-cell-tropin, is ACTH22–39 | Q38354936 | ||
| The Medical Research Council trial of short-term high-dose alternate day prednisolone in idiopathic membranous nephropathy with nephrotic syndrome in adults. The MRC Glomerulonephritis Working Party | Q38929940 | ||
| Characterization of the sea bass melanocortin 5 receptor: a putative role in hepatic lipid metabolism | Q39774322 | ||
| Direct glucocorticoid inhibition of insulin secretion. An in vitro study of dexamethasone effects in mouse islets | Q39777522 | ||
| Melanocortin 5 receptor activates ERK1/2 through a PI3K-regulated signaling mechanism. | Q39853875 | ||
| Hepatocyte growth factor suppresses proinflammatory NFkappaB activation through GSK3beta inactivation in renal tubular epithelial cells | Q40024086 | ||
| Adrenocorticotrophin and corticosteroid changes during dexamethasone infusion to intact and synacthen infusion to hypophysectomized foetuses | Q40121182 | ||
| Corticotropin in human plasma general considerations | Q40141956 | ||
| Melanocortin-3 receptor activates MAP kinase via PI3 kinase | Q40190529 | ||
| Alpha-melanocyte-stimulating hormone suppresses antigen-induced lymphocyte proliferation in humans independently of melanocortin 1 receptor gene status | Q40370257 | ||
| ACTH stimulates insulin secretion from MIN6 cells and primary mouse and human islets of Langerhans. | Q40601743 | ||
| Improving pharmacokinetic properties of adrenocorticotropin by site-specific lipid modification | Q40638858 | ||
| The melanocortin receptors: agonists, antagonists, and the hormonal control of pigmentation | Q41028982 | ||
| Diagnosis and management of glomerular diseases | Q41484969 | ||
| Pathogenesis of lipoid nephrosis: a disorder of T-cell function | Q41509804 | ||
| Evidence that glycosylation of pro-opiocortin and ACTH influences their proteolysis by trypsin and blood proteases | Q41549530 | ||
| New mechanisms of glucocorticoid-induced insulin resistance: make no bones about it. | Q41626209 | ||
| A.C.T.H. in nephrosis | Q41706165 | ||
| Rac1 mediates dendrite formation in response to melanocyte stimulating hormone and ultraviolet light in a murine melanoma model | Q42459634 | ||
| Treatment of resistant glomerular diseases with adrenocorticotropic hormone gel: a prospective trial | Q42654718 | ||
| Focal segmental glomerulosclerosis in a patient with isolated ACTH deficiency and reversible hypothyroidism | Q43265903 | ||
| Insulin release after ACTH, glucagon and adenosine-3'-5'-phosphate (cyclic AMP) in the perfused isolated rat pancreas | Q44313382 | ||
| Molecular engineering of short half-life small peptides (VIP, αMSH and γ₃MSH) fused to latency-associated peptide results in improved anti-inflammatory therapeutics | Q44687204 | ||
| Bone loss is more severe in primary adrenal than in pituitary-dependent Cushing's syndrome | Q44807843 | ||
| Activation of MAP kinase by MC4-R through PI3 kinase | Q44921489 | ||
| ACTH therapy in nephrotic syndrome induced by idiopathic membranous nephropathy. | Q45167590 | ||
| The effect of alpha-melanocyte-stimulating hormone on renal tubular cell apoptosis and tubulointerstitial fibrosis in cyclosporine A nephrotoxicity | Q45197915 | ||
| Modulation by dietary sodium intake of melanocortin 3 receptor mRNA and protein abundance in the rat kidney | Q45224292 | ||
| Modulation of blood pressure by central melanocortinergic pathways | Q46192750 | ||
| A randomized pilot trial comparing methylprednisolone plus a cytotoxic agent versus synthetic adrenocorticotropic hormone in idiopathic membranous nephropathy | Q46907543 | ||
| ACTH-induced improvement in the nephrotic syndrome in patients with a variety of diagnoses | Q47717220 | ||
| alpha-melanocyte-stimulating hormone inhibits NF-kappaB activation and IkappaBalpha degradation in human glioma cells and in experimental brain inflammation | Q48189680 | ||
| A randomized controlled trial of prednisone in patients with idiopathic membranous nephropathy. | Q50557738 | ||
| Change of melanocortin receptor expression in rat kidney ischemia-reperfusion injury. | Q53529916 | ||
| Effect of administration of ACTH on insulin secretion in dogs. | Q53755530 | ||
| Beneficial effects of ACTH on the serum lipoprotein profile and glomerular function in patients with membranous nephropathy. | Q54077444 | ||
| Quantitative measurement of the levels of melanocortin receptor subtype 1, 2, 3 and 5 and pro-opio-melanocortin peptide gene expression in subsets of human peripheral blood leucocytes. | Q54674363 | ||
| Experimental metastasis correlates with cyclic AMP accumulation in B16 melanoma clones | Q59070352 | ||
| Tall stature in familial glucocorticoid deficiency | Q62750321 | ||
| A glomerular permeability factor produced by human T cell hybridomas | Q67851043 | ||
| Hypersensitivity to different ACTH peptides | Q68664753 | ||
| Evidence suggesting under-treatment in adults with idiopathic focal segmental glomerulosclerosis. Regional Glomerulonephritis Registry Study | Q69009531 | ||
| Increased experimental metastatic capacity of a murine melanoma following induction of differentiation | Q69508707 | ||
| Hypothalamic control of lipid metabolism | Q70084475 | ||
| Evaluation and management of corticotropin allergy | Q70179702 | ||
| Levamisole as immunostimulant in the clinical practice | Q70810759 | ||
| Primary nephrotic syndrome in children: clinical significance of histopathologic variants of minimal change and of diffuse mesangial hypercellularity. A Report of the International Study of Kidney Disease in Children | Q71087118 | ||
| Stimulation of insulin secretion from mouse pancreatic islets, maintained in tissue culture, by the pituitary neurointermediate lobe of the genetically obese mouse (obob) | Q72864445 | ||
| Thrombotic microangiopathic haemolytic anaemia (thrombotic microangiopathy) | Q73953443 | ||
| P433 | issue | 2 | |
| P304 | page(s) | 134-151 | |
| P577 | publication date | 2014-03-01 | |
| P1433 | published in | Advances in Chronic Kidney Disease | Q15763121 |
| P1476 | title | Leveraging melanocortin pathways to treat glomerular diseases | |
| P478 | volume | 21 |
| Q38667777 | Acquired Resistance to Corticotropin Therapy in Nephrotic Syndrome: Role of De Novo Neutralizing Antibody |
| Q35976834 | Acthar gel in the treatment of nephrotic syndrome: a multicenter retrospective case series |
| Q92531741 | Adrenocorticotropic Hormone in the Treatment of Focal Segmental Glomerulosclerosis Following Kidney Transplantation |
| Q37070458 | Adrenocorticotropic hormone analog use for podocytopathies |
| Q37651364 | Adrenocorticotropic hormone therapy for the treatment of idiopathic nephrotic syndrome in children and young adults: a systematic review of early clinical studies with contemporary relevance |
| Q38703169 | Clinical and Economic Evaluation of Repository Corticotropin Injection: A Narrative Literature Review of Treatment Efficacy and Healthcare Resource Utilization for Seven Key Indications |
| Q53818437 | Complete Remission of Post-transplantation Recurrence of Focal Segmental Glomerulosclerosis With the Use of Adrenocorticotrophic Hormone Gel: Case Report. |
| Q38610760 | Developments and new vistas in the field of melanocortins. |
| Q38858772 | Efficacy and safety of adrenocorticotropic hormone treatment in glomerular diseases: a systematic review and meta-analysis |
| Q47212986 | GPCRs as targets for approved drugs: How many targets and how many drugs? |
| Q41467613 | Low-dose synthetic adrenocorticotropic hormone-analog therapy for nephrotic patients: results from a single-center pilot study. |
| Q57813728 | Management of steroid-resistant nephrotic syndrome in children and adolescents |
| Q46594445 | Melanocortin 1 receptor agonist protects podocytes through catalase and RhoA activation. |
| Q26865343 | Melanocortin peptides: potential targets in systemic lupus erythematosus |
| Q41688065 | Multiple Targets for Novel Therapy of FSGS Associated with Circulating Permeability Factor |
| Q64230728 | New strategies and perspectives on managing IgA nephropathy |
| Q90430043 | Relapse of Nephrotic Syndrome after Adrenocorticotropic Hormone-Induced Remission: Implications of Adrenocorticotropic Hormone Antibodies |
| Q35219562 | Repository corticotropin injection in a patient presenting with focal segmental glomerulosclerosis, rheumatoid arthritis, and optic neuritis: a case report |
| Q26746146 | Sex-specific effects of LiCl treatment on preservation of renal function and extended life-span in murine models of SLE: perspective on insights into the potential basis for survivorship in NZB/W female mice |
| Q90685929 | Targeting Regulatory T Cells for Transplant Tolerance: New Insights and Future Perspectives |
| Q37139449 | The podocyte as a direct target for treatment of glomerular disease? |
| Q98178834 | Use of Repository Corticotropin Gel (Acthar) in Progressive Nephrotic Syndrome Secondary to Transplant Glomerulopathy: A Report of Three Cases |
Search more.